Clinical Trial Update: Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD) [Phase 2]

View source ↗

Summary

Phase 2 results for metadoxine extended-release in attention-deficit/hyperactivity disorder (ADHD) are reported, describing efficacy and safety outcomes from th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Metadoxine (metadoxine)

Snippet

Sponsor: Alcobra Ltd. | Conditions: ADHD | Phase 2 | Status: COMPLETED | Results posted: 2012-04-18